Gamma-Fagarine

Gamma-Fagarine

SCHEMBL679918

COc1c2ccoc2nc2c(OC)cccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 1.00
ALDH1A1 P00352 11/20 1.00
HPGD P15428 9/20 1.00
HSD17B10 Q99714 5/20 0.71
MEN1 O00255 3/20 0.71
KMT2A Q03164 3/20 0.71
CYP3A4 P08684 3/20 0.71
TP53 P04637 2/20 0.71
CYP1A2 P05177 2/20 0.71
LMNA P02545 2/20 0.71
CYP2D6 P10635 1/20 0.71
TSHR P16473 1/20 0.71
CYP2C19 P33261 1/20 0.71
TUBB4A P04350 1/20 0.58
TUBB P07437 1/20 0.58
TUBA3C P0DPH7 1/20 0.58
TUBA1B P68363 1/20 0.58
TUBA4A P68366 1/20 0.58
TUBB4B P68371 1/20 0.58
TUBB3 Q13509 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gamma-Fagarine SCHEMBL29594141 1.00 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10MEN1
Robustine SCHEMBL29351281 0.84 KDM4E (0.72) KDM4EALDH1A1HPGDHSD17B10MEN1
Robustine SCHEMBL31419857 0.84 KDM4E (0.72) KDM4EALDH1A1HPGDHSD17B10MEN1
Robustine SCHEMBL28488147 0.84 KDM4E (0.72) KDM4EALDH1A1HPGDHSD17B10MEN1
Skimmianine SCHEMBL29594332 0.83 ALDH1A1 (1.00) KDM4EALDH1A1HPGDHSD17B10MEN1
Skimmianine SCHEMBL893654 0.83 ALDH1A1 (1.00) KDM4EALDH1A1HPGDHSD17B10MEN1
Skimmianine SCHEMBL6933482 0.80 ALDH1A1 (0.80) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL31214315 0.79 ALDH1A1 (0.66) KDM4EALDH1A1HPGDHSD17B10MEN1
Dictamnine SCHEMBL1760700 0.76 POLB (0.65) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL15263337 0.76 ALDH1A1 (0.71) KDM4EALDH1A1HPGDHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4229639-A1 METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE GBS Global Biopharma, Inc. (CA) 2023-08-23 EP claimed
WO-2022081889-A1 METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE GBS GLOBAL BIOPHARMA, INC. (CA) 2022-04-21 WO claimed
EP-3500271-A1 GENOME EDITING ENHANCERS Bluebird Bio, Inc. (US) 2019-06-26 EP claimed
US-20190169597-A1 GENOME EDITING ENHANCERS BLUEBIRD BIO, INC. (US) 2019-06-06 US claimed
CN-109715171-A Genome editor's enhancer 蓝鸟生物公司 2019-05-03 CN claimed
CN-109394870-A The preparation method at anticancer activity position, content assaying method and its application in cortex dictamni 哈尔滨职业技术学院 2019-03-01 CN claimed
CN-106539804-B A kind of molecule traditional Chinese medicine frostlike-powder and preparation method thereof for relief from osteoarthritis pain 福建中医药大学 2018-12-21 CN claimed
CN-108354937-A The new pharmaceutical uses of fagarine 上海壹志医药科技有限公司 2018-08-03 CN claimed
WO-2018035423-A1 GENOME EDITING ENHANCERS BLUEBIRD BIO, INC. (US) 2018-02-22 WO claimed
CN-107629065-A A kind of method of separation and concentration furoquinoline Alkaloid in skin from Dictamnus angustifolius 中国药科大学 2018-01-26 CN claimed
EP-2654727-A1 METHODS OF PRODUCING STABILIZED SOLID DOSAGE PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS Mallinckrodt LLC (US) 2013-10-30 EP claimed
US-20130273153-A1 Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans MNK 2011 LLC (F/K/A MALLINCKRODT INC.) 2013-10-17 US claimed
WO-2012087377-A1 METHODS OF PRODUCING STABILIZED SOLID DOSAGE PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS MALLINCKRODT LLC (US) 2012-06-28 WO claimed
US-20110287095-A1 Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans Mallinkckrodt Inc. (US) 2011-11-24 US claimed
WO-2011087765-A2 METHODS OF PRODUCING STABILIZED SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS MALLINCKRODT INC. (US) 2011-07-21 WO claimed
US-20110150989-A1 Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans Mallinkckrodt Inc. (US) 2011-06-23 US claimed
WO-2011041470-A2 SUSTAINED-RELEASE OPIATE AND OPIATE DERIVATIVE COMPOSITIONS MALLINCKRODT INC. (US) 2011-04-07 WO claimed
US-20110077222-A1 Sustained-Release Opiate and Opiate Derivative Compositions MALLINCKRODT INC. (US) 2011-03-31 US claimed
EP-0496349-B1 Coating solution for preventing adhesion of polymer scale and method for its use SHINETSU CHEMICAL CO (JP) 1996-04-10 EP claimed
US-4767626-A ALKALOID EXTRACT OF ZANTHOXYLUM SIMULANS CHENG THEODORE (US) 1988-08-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110150989-A1 Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans LPXN, FSCN1, NCLN KDM4E 4729/4885ALDH1A1 3382/4885HPGD 1410/4885
US-20110287095-A1 Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans LPXN, FSCN1, NCLN KDM4E 4729/4885ALDH1A1 3382/4885HPGD 1410/4885
US-20110077222-A1 Sustained-Release Opiate and Opiate Derivative Compositions OPRL1, OPRK1, OPRM1 KDM4E 3460/4885ALDH1A1 896/4885HPGD 767/4885
US-20130273153-A1 Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans LPXN, FSCN1, NCLN KDM4E 4729/4885ALDH1A1 3382/4885HPGD 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.